Neonatal Cardiovascular Function after Antenatal Sildenafil for Severe, Early-Onset Intrauterine Growth Restriction: A Substudy of the STRIDER-NZAus Randomized Placebo-Controlled Trial

Sarah L Harris; Chris McKinlay; Katie Groom; Friederike Beker; Anuradha Kochar; Andrew Gill

doi:10.1016/j.ympdx.2019.100009

Neonatal Cardiovascular Function after Antenatal Sildenafil for Severe, Early-Onset Intrauterine Growth Restriction: A Substudy of the STRIDER-NZAus Randomized Placebo-Controlled Trial

J Pediatr X. 2019 Nov 20:1:100009. doi: 10.1016/j.ympdx.2019.100009. eCollection 2019 Spring.

Authors

Sarah L Harris^{1

2}, Chris McKinlay³, Katie Groom^{3

4}, Friederike Beker^{5

6}, Anuradha Kochar⁷, Andrew Gill⁸

Affiliations

¹ University of Otago, Christchurch, New Zealand.
² Canterbury District Health Board, Christchurch, New Zealand.
³ University of Auckland, Auckland, New Zealand.
⁴ National Women's Health, Auckland City Hospital, Auckland, New Zealand.
⁵ Mater Research Institute, University of Queensland, South Brisbane, Queensland, Australia.
⁶ Neonatal Critical Care Unit, Mater Mothers Hospital, South Brisbane, Queensland, Australia.
⁷ Women's and Children's Hospital, Adelaide, Australia.
⁸ Center of Neonatal Research and Education, University of Western Australia, Perth, Australia.

Abstract

We evaluated the effect of antenatal sildenafil on neonatal cardiovascular function in a subgroup of 27 infants of mothers participating in the STRIDER-NZAus randomized controlled trial. In this small study, we found no association between antenatal sildenafil and neonatal cardiac dysfunction including no pulmonary hypertension in exposed or unexposed infants.

Publication types

Case Reports